封面
市场调查报告书
商品编码
1778939

额颞叶失智症市场-全球产业规模、份额、趋势、机会和预测,按药物类别、疾病适应症、配销通路、地区和竞争细分,2020 年至 2030 年

Frontotemporal Dementia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Disease Indication, By Distribution Channel, By Region & Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球额颞叶失智症市场价值为 2.4136 亿美元,预计在预测期内将呈现强劲成长,到 2030 年的复合年增长率为 6.39%。额颞叶疾病是一种神经系统疾病,其特征是大脑额叶或颞叶神经细胞的退化。这种疾病包括失智症、进行性核上性麻痹和原发性进行性失语症,会严重影响行为、语言、运动和个性,进而损害个人的日常活动能力。额颞叶疾病,也称为额颞叶退化,是一种主要影响额叶和颞叶的脑部疾病。这种疾病的特征是神经细胞逐渐丧失和痴呆症的发展。

市场概览
预测期 2026-2030
2024年市场规模 2.4136亿美元
2030年市场规模 3.4718亿美元
2025-2030 年复合年增长率 6.39%
成长最快的领域 认知增强剂
最大的市场 北美洲

例如,芬兰的一项2025年研究比较了245名额颞叶失智症 (FTD) 患者、1300多名阿兹海默症 (AD) 患者以及2400多名年龄、性别和地点匹配的健康对照者的癫痫盛行率和抗癫痫药物使用情况。 FTD 患者的平均诊断年龄为65岁(女性占49%),而AD患者的平均诊断年龄为72岁(女性占59%)。额颞叶失智症的典型发病年龄范围为40至60岁,但也可能在60岁以后发病。确诊后,患者的平均寿命约为8-10年。鑑于其对医疗保健行业的重大影响,预计额颞叶失智症在预测期内将大幅增长。

关键市场驱动因素

加大FTD药物研发投入与资金投入

主要市场挑战

神经系统疾病的误诊

主要市场趋势

更高的药品审批和先进的治疗

目录

第 1 章:产品概述

第二章:研究方法

第三章:执行摘要

第四章:顾客之声

第五章:临床试验分析

第六章:全球额颞叶失智症市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依药物类别(认知增强剂、抗精神病药、抗忧郁剂、中枢神经兴奋剂和其他药物类别)
    • 依疾病指征(额颞叶失智症、原发性进行性失语症及运动障碍)
    • 按配销通路(医院药房、零售药房和网路药房)
    • 按地区
    • 按公司分类(2024)
  • 市场地图

第七章:北美额颞叶失智症市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美:国家分析
    • 美国
    • 加拿大
    • 墨西哥

第八章:欧洲额颞叶失智症市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲:国家分析
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙

第九章:亚太地区额颞叶失智症市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区:国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第十章:南美额颞叶失智症市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲:国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 11 章:中东和非洲额颞叶失智症市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA:国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 12 章:市场动态

  • 驱动程式
  • 挑战

第十三章:市场趋势与发展

  • 近期发展
  • 併购
  • 产品发布

第 14 章:全球额颞叶失智症市场:SWOT 分析

第 15 章:波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 16 章:竞争格局

  • Transposon Therapeutics
  • Alector Inc.
  • Denali Therapeutics Inc.
  • Pfizer Inc.
  • Johnson & Johnson Services Inc.
  • Prevail Therapeutics
  • Wave Life Sciences
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • TauRx Pharmaceuticals Ltd.

第 17 章:策略建议

第18章调查会社について・免责事项

简介目录
Product Code: 4841

Global Frontotemporal Dementia Market was valued at USD 241.36 Million in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 6.39% through 2030F. Frontotemporal diseases are a neurological condition characterized by the degeneration of nerve cells in the frontal or temporal lobes of the brain. This condition, which includes dementia, progressive supranuclear palsy, and primary progressive aphasia, significantly impacts behavior, language, movement, and personality, thereby impairing individuals' ability to perform daily activities. Frontotemporal disorders, also known as frontotemporal lobar degeneration, are a type of brain disorder that primarily affects the frontal and temporal lobes. This condition is characterized by the progressive loss of nerve cells and the development of dementia.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 241.36 Million
Market Size 2030USD 347.18 Million
CAGR 2025-20306.39%
Fastest Growing SegmentCognitive Enhancers
Largest MarketNorth America

For instance, a 2025 study from Finland compared epilepsy prevalence and antiseizure medication use among 245 frontotemporal dementia (FTD) patients, over 1,300 Alzheimer's disease (AD) patients, and more than 2,400 age-, sex-, and location-matched healthy controls. FTD patients had a mean diagnosis age of 65 (49% women), while AD patients averaged 72 years (59% women). The typical age range for the onset of frontotemporal disorder is between 40 and 60 years, although it can occur after the age of 60. Following diagnosis, the average life expectancy is approximately 8-10 years. Given its significant impact on the healthcare sector, it is projected that frontotemporal disorders will experience substantial growth in the forecast period.

Key Market Drivers

Increasing FTD Drug Development and Increasing Funds

Non-profit organizations and disease advocacy groups, as well as private organizations, are currently focused on supporting the development of drugs for Frontotemporal Degeneration (FTD) due to the expanding patient population. Research funding initiatives from notable non-profit organizations, such as the Association for Frontotemporal Degeneration (AFTD), Bluefield Project Organization, Tau Consortium Organization, Alzheimer Discovery Foundation (ADDF), and CurePSP, Inc., have played a significant role in stimulating research efforts for the treatment of frontotemporal disorders. These organizations provide support for both clinical and preclinical trials aimed at testing novel therapeutics that can intervene to slow down or halt the progression of FTD and other rare neurological diseases. This, in turn, contributes to the growth of the market. For instance, a 2025 study revealed that epileptic seizures are significantly more common in patients with frontotemporal dementia (FTD) than previously believed. This finding enhances understanding of FTD symptoms and highlights the need to consider seizures in patient care. Led by Neurocenter Finland, the University of Eastern Finland and University of Oulu conducted the research, published in JAMA Neurology, using one of the world's largest FTD datasets.

Grants and funding provide resources to support FTD-focused research initiatives. This includes investigations into the underlying mechanisms of the disease, identification of potential drug targets, and the development of novel therapeutic approaches. Drug development in FTD necessitates rigorous clinical trials to evaluate the safety and efficacy of potential treatments. Grants and funding support the design, implementation, and monitoring of these trials, facilitating the testing of new therapies. Adequate funding enhances the attractiveness of FTD research for scientists and researchers. This can lead to increased participation, collaboration, and expertise focused on FTD drug development efforts. Funding enables the exploration of innovative therapeutic strategies, including small molecules, biologics, gene therapies, and personalized medicine approaches tailored to the unique characteristics of FTD patients. Grants and funding assist in the identification and validation of promising drug targets for FTD. This step is crucial in developing treatments that address the underlying causes of the disease.

Key Market Challenges

Misdiagnosis of Neurological Disorders

Multiple frontotemporal disorders are frequently misdiagnosed as depression, Parkinson's disease, Alzheimer's disease, or other psychiatric conditions. This hinders the potential for implementing appropriate treatment for neurological conditions. Misdiagnosis often leads to delayed initiation of appropriate treatment for the underlying FTD. This can result in missed opportunities for interventions that could slow disease progression or manage symptoms effectively. Treating FTD patients based on misdiagnosed conditions can result in ineffective or even harmful treatments. Medications commonly used for depression or other psychiatric disorders may not address the specific cognitive, behavioral, and functional challenges of FTD. Without proper treatment, FTD symptoms can worsen over time, leading to greater impairment in daily functioning and quality of life. Misdiagnosis can lead to unnecessary medical expenses, as well as wasted time and resources on treatments that are unlikely to be effective. Accurate diagnosis is crucial for enrolling eligible patients in clinical trials for FTD-specific treatments. Misdiagnosis can exclude patients from potential participation and hinder the development of targeted therapies.

Key Market Trends

Higher Drug Approvals and Advanced Treatment

Several antidepressant drugs are utilized for the treatment of major depressive disorders and other conditions, such as dysthymia, obsessive-compulsive disorder (OCD), anxiety disorders, eating disorders, chronic pain, and neuropathic pain. For example, in October 2018, Lundbeck introduced Brintellix tablets for the treatment of Major Depressive Disorder in India. Similarly, in April 2019, Lupin launched antidepressant Fluoxetine tablets in the American market, specifically for the treatment of major depressive disorder and obsessive-compulsive disorder. These initiatives contribute significantly to the growth of the market.

Drug approvals provide patients with access to treatments that can potentially slow down disease progression, manage symptoms, and improve quality of life. This leads to higher demand for treatments among FTD patients and healthcare providers. Effective treatments often come with improved diagnostic methods, biomarkers, and screening tools. This facilitates early diagnosis and patient identification, leading to an increased pool of eligible patients seeking treatment. Approved treatments can contribute to better patient outcomes, including improved cognitive function, reduced behavioral symptoms, and enhanced daily functioning. Positive outcomes drive higher demand for these treatments. Drug approvals garner media attention and raise awareness among patients, caregivers, and the general public. This increased awareness leads to more individuals seeking diagnosis and treatment options for FTD. Successful drug approvals indicate a growing interest in FTD research and development. This encourages pharmaceutical companies, researchers, and investors to invest more resources into finding innovative treatments.

Key Market Players

  • Transposon Therapeutics
  • Alector Inc.
  • Denali Therapeutics Inc.
  • Pfizer Inc.
  • Johnson & Johnson Services Inc.
  • Prevail Therapeutics
  • Wave Life Sciences
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • TauRx Pharmaceuticals Ltd.

Report Scope:

In this report, the Global Frontotemporal Dementia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Frontotemporal Dementia Market, By Drug Class:

  • Cognitive Enhancers
  • Antipsychotics
  • Antidepressants
  • CNS Stimulants
  • Other Drug Classes

Frontotemporal Dementia Market, By Disease Indication:

  • Frontotemporal Dementia
  • Primary Progressive Aphasia
  • Movement Disorders

Frontotemporal Dementia Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Frontotemporal Dementia Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Frontotemporal Dementia Market.

Available Customizations:

Global Frontotemporal Dementia market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Application
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Frontotemporal Dementia Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class (Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants, and Other Drug Classes)
    • 6.2.2. By Disease Indication (Frontotemporal Dementia, Primary Progressive Aphasia, and Movement Disorders)
    • 6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
    • 6.2.4. By Region
    • 6.2.5. By Company (2024)
  • 6.3. Market Map

7. North America Frontotemporal Dementia Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Disease Indication
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Frontotemporal Dementia Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Disease Indication
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Canada Frontotemporal Dementia Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Disease Indication
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Mexico Frontotemporal Dementia Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Disease Indication
        • 7.3.3.2.3. By Distribution Channel

8. Europe Frontotemporal Dementia Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Disease Indication
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. Germany Frontotemporal Dementia Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Disease Indication
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. United Kingdom Frontotemporal Dementia Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Disease Indication
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Italy Frontotemporal Dementia Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecasty
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Disease Indication
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. France Frontotemporal Dementia Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Disease Indication
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Spain Frontotemporal Dementia Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Disease Indication
        • 8.3.5.2.3. By Distribution Channel

9. Asia-Pacific Frontotemporal Dementia Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Disease Indication
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Frontotemporal Dementia Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Disease Indication
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. India Frontotemporal Dementia Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Disease Indication
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Japan Frontotemporal Dementia Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Disease Indication
        • 9.3.3.2.3. By Distribution Channel
    • 9.3.4. South Korea Frontotemporal Dementia Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Drug Class
        • 9.3.4.2.2. By Disease Indication
        • 9.3.4.2.3. By Distribution Channel
    • 9.3.5. Australia Frontotemporal Dementia Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Drug Class
        • 9.3.5.2.2. By Disease Indication
        • 9.3.5.2.3. By Distribution Channel

10. South America Frontotemporal Dementia Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Disease Indication
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Frontotemporal Dementia Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Disease Indication
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Argentina Frontotemporal Dementia Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Disease Indication
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Colombia Frontotemporal Dementia Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Disease Indication
        • 10.3.3.2.3. By Distribution Channel

11. Middle East and Africa Frontotemporal Dementia Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Class
    • 11.2.2. By Disease Indication
    • 11.2.3. By Distribution Channel
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Frontotemporal Dementia Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Drug Class
        • 11.3.1.2.2. By Disease Indication
        • 11.3.1.2.3. By Distribution Channel
    • 11.3.2. Saudi Arabia Frontotemporal Dementia Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Drug Class
        • 11.3.2.2.2. By Disease Indication
        • 11.3.2.2.3. By Distribution Channel
    • 11.3.3. UAE Frontotemporal Dementia Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Drug Class
        • 11.3.3.2.2. By Disease Indication
        • 11.3.3.2.3. By Distribution Channel

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Development
  • 13.2. Mergers & Acquisitions
  • 13.3. Product Launches

14. Global Frontotemporal Dementia Market: SWOT Analysis

15. Porter's Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Product

16. Competitive Landscape

  • 16.1. Transposon Therapeutics
  • 16.2. Alector Inc.
  • 16.3. Denali Therapeutics Inc.
  • 16.4. Pfizer Inc.
  • 16.5. Johnson & Johnson Services Inc.
  • 16.6. Prevail Therapeutics
  • 16.7. Wave Life Sciences
  • 16.8. AstraZeneca plc
  • 16.9. GlaxoSmithKline plc
  • 16.10. TauRx Pharmaceuticals Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer